Date: 2014-01-21
Type of information: Financing round
Company: Synthelis (France)
Investors: Alpes Developpement Durable Investissement (A2D-Invest) (France), Grenoble Angels (France), Rhone-Alpes Creation (France), Savoie Angels (France), SudRhoneAlpes Capital (France), Viaduc Participations (France)
Amount: € 610,000
Funding type:
Planned used: The funds will be used to speed up the development of toll manufacturing services for membrane proteins for use by R&D departments in the pharmaceutical and biotechnology industries. The funding also gives the company scope to consolidate and expand its functional and structural characterization services.
Others: * On January 21, 2014, Synthelis, a French company specializing in the production and characterization of therapeutic targets and antigens, has announced that it has secured initial backing of € 610,000 from a group of French investors comprising Rhone-Alpes Creation, Alpes Developpement Durable Investissement (A2D-Invest), Sud Rhone-Alpes Capital, Viaduc and the Savoy and Grenoble Business Angels networks.
The company has been founded in 2011 on the basis of Professor Jean-Luc Lenormand\'s work at the TIMC-TheREx laboratory (Universite Joseph Fourier). Synthelis develops and leverages a patented technology for the acellular production of membrane proteins in the presence of liposomes. The technology preserves the structure and the natural properties of these molecules, along with their ‘transportability’. In two years, Synthelis has produced over 50 membrane proteins as part of more than 20 projects undertaken in conjunction with internationally-renowned pharmaceutical organizations. The success rate for protein expression across all the work undertaken by Synthelis to date is in excess of 90 per cent.
Once the initial commercial objectives have been achieved, new investment is planned in order to industrialize Synthelis’ acellular procedure and consolidate its position in this market. The funding will open up the market for contract manufacturing services, complementing and ensuring continuity with the existing contract research offering.
Therapeutic area:
